NCCN updated guidelines to recommend CSF-based molecular tumor profiling for patients with high-grade glioma or glioblastoma when tissue biopsy is not feasible. The update supports CSF testing as an adjunct in cases where molecular markers are needed for diagnosis and treatment decisions, including H3K27-altered tumors.